Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3438 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Mariska van der Plas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Galapagos NV, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Methotrexate, Sulfasalazine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
GLPG3970 is a selective salt‐inducible kinase 2/3 inhibitor intended for the treatment of inflammatory diseases. In vitro studies suggest GLPG3970 strongly inhibits breast cancer resistance protein (BCRP), indicating a possible interaction with BCRP substrates such as sulfasalazine (SSZ; a probe substrate for intestinal BCRP inhibition) and methotrexate (MTX), both inflammatory disease medications. Two open‐label, nonrandomized, phase I, drug–drug interaction (DDI) studies assessed the pharmacokinetics of SSZ 1,000 mg (NCT04720183) and MTX 7.5 mg (EudraCT: 2020‐000391‐37) with and without GLPG3970 350 mg. Healthy participants aged 18–55 years with wild‐type homozygous BCRP genotype (c421C/C) received: SSZ on day (D)1, GLPG3970 + SSZ on D5, and GLPG3970 2 hours after SSZ on D9 ( N = 8; SSZ/GLPG3970 DDI study); MTX on D1, GLPG3970 + MTX on D5, and GLPG3970 on D6–8 ( N = 15; MTX/GLPG3970 DDI study). Primary end points were AUC and C max (“exposure”) of SSZ and its metabolite (sulfapyridine [SPD]), SPD:SSZ AUC ratio (SSZ/GLPG3970 study), and AUC and C max (“exposure”) of MTX (MTX/GLPG3970 study). DDIs were evaluated using the geometric mean ratio of each end point; a > 2‐fold increase in SSZ or MTX exposure was deemed clinically relevant. GLPG3970 demonstrated mild inhibition of intestinal BCRP in vivo : GLPG3970 + SSZ increased SSZ exposure ~1.7–1.8‐fold and decreased SPD:SSZ ratio ~ 2‐fold vs. SSZ alone. GLPG3970 administered 2 hours after SSZ did not change the magnitude of the interaction. GLPG3970 + MTX had no relevant effect on MTX pharmacokinetics vs. MTX alone. Therefore, the strong in vitro BCRP inhibition was not confirmed in vivo . No safety concerns were observed when GLPG3970 was coadministered with SSZ or MTX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Galapagos NV, Leiden, The Netherlands.
- Galapagos SASU, Romainville, France.
- Galapagos NV, Mechelen, Belgium.
ORCID-Profile: Mariska van der Plas, Justine Dao, Volha Zabela, Fien Gistelinck, Susan Bellaire
Zitieren
APA
van der Plas, M., Dao, J., Zabela, V., Gistelinck, F., & Bellaire, S. (2025). Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3438
Vancouver
van der Plas M, Dao J, Zabela V, Gistelinck F, Bellaire S. Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3438
BibTeX
@article{vanderPlas2025,
author = {van der Plas, Mariska and Dao, Justine and Zabela, Volha and Gistelinck, Fien and Bellaire, Susan},
title = {Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3438}
}
EUVIMED